Bausch Health Companies | VRX - Equity Capital And Reserves


Bausch Health Companies reported $-2.06B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Amgen USD 9.19B 532M Mar/2026
ANI Pharmaceuticals USD 562.3M 21.58M Mar/2026
Aurora Cannabis CAD 536.36M 30.74M Dec/2025
Bausch Health Companies USD -2.06B 1.5B Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Canopy Growth CAD 758.17M 22.16M Dec/2025
Corcept Therapeutics USD 637.99M 9.82M Mar/2026
Danaher USD 52.95B 415M Mar/2026
Drreddys Laboratories INR 4.14B 107.72M Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Novo Nordisk DKK 203.07B 9.02B Mar/2026
Pacira USD 653.89M 39.22M Mar/2026
Perrigo USD 2.5B 436.7M Mar/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 1.89B 58.06M Mar/2026
Supernus Pharmaceuticals USD 1.08B 15.09M Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026
Zoetis USD 3.23B 98M Mar/2026